Vaxart, Inc. (VXRT): Free Cash Flow
$7.57M
Year ended 2025-12-31
$33.38M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.57M | n/m | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | -$45.32M | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | -$72.32M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$104.38M | n/m | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | -$64.99M | n/m | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | -$24.97M | n/m | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | -$13.94M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$15.26M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$10.16M | n/a | 2019-02-06, From 2017-01-01 |
| No annual figure between 2015-06-30 and 2017-12-31. | |||
| 2015-06-30 | -$9.70M | n/m | 2016-09-13, From 2014-07-01 |
| 2014-06-30 | -$3.40M | n/m | 2016-09-13, From 2013-07-01 |
| 2013-06-30 | -$14.90M | n/m | 2015-09-11, From 2012-07-01 |
| 2012-06-30 | -$17.20M | n/m | 2014-09-30, From 2011-07-01 |
| 2011-06-30 | -$34.40M | n/a | 2013-09-27, From 2010-07-01 |
| No annual figure between 2009-12-26 and 2011-06-30. | |||
| 2009-12-26 | $6.21M | n/a | 2012-03-14, From 2008-12-28 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.57M | n/m |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$336.24M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $24.75M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$48.95M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | -$74.09M | n/m |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | -$126.38M | n/m |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | -$178.72M | n/m |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$75.63M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $188.91M | +58.5% |
Compare VXRT, IOVA, VCEL, ADPT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗